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A loop of cancer-stroma-cancer interaction promotes
peritoneal metastasis of ovarian cancer via TNFα-TGFα-
EGFR
T-S Lau1, LK-Y Chan1, EC-H Wong2, CW-C Hui2, K Sneddon1, T-H Cheung1, S-F Yim1, JH-S Lee1, CS-Y Yeung1, TK-H Chung1 and J Kwong1
Peritoneum is the most common site for ovarian cancer metastasis. Here we investigate how cancer epigenetics regulates
reciprocal tumor-stromal interactions in peritoneal metastasis of ovarian cancer. Firstly, we ﬁnd that omental stromal ﬁbroblasts
enhance colony formation of metastatic ovarian cancer cells, and de novo expression of transforming growth factor-alpha (TGF-α) is
induced in stromal ﬁbroblasts co-cultured with ovarian cancer cells. We also observed an over-expression of tumor necrosis factor-
alpha (TNF-α) in ovarian cancer cells, which is regulated by promoter DNA hypomethylation as well as chromatin remodeling.
Interestingly, this ovarian cancer-derived TNF-α induces TGF-α transcription in stromal ﬁbroblasts through nuclear factor-κB (NF-κB).
We further show that TGF-α secreted by stromal ﬁbroblasts in turn promotes peritoneal metastasis of ovarian cancer through
epidermal growth factor receptor (EGFR) signaling. Finally, we identify a TNFα-TGFα-EGFR interacting loop between tumor and
stromal compartments of human omental metastases. Our results therefore demonstrate cancer epigenetics induces a loop of
cancer-stroma-cancer interaction in omental microenvironment that promotes peritoneal metastasis of ovarian cancer cells via
TNFα-TGFα-EGFR.
Oncogene (2017) 36, 3576–3587; doi:10.1038/onc.2016.509; published online 6 February 2017
INTRODUCTION
Ovarian cancer is a serious health problem worldwide. A majority
(475%) of ovarian cancer patients were diagnosed at late stage
(stage III and IV) at which cancer cells have already disseminated
and metastasized to the peritoneum and/or distant organs.1
Although about 80% of the patients with advanced ovarian
cancers initially respond to the ﬁrst-line treatment (including
surgical debulking and platinum-based post-operative chemother-
apy), residual diseases will progress into chemo-resistant ovarian
cancer and relapse within 16–22 months in most of the patients.
This is the reason why the 5-year survival rate of patients with
stage III and IV ovarian cancer remains in an unsatisfactory level
(17–39%; www.cancer.org).2,3 By understanding the cellular and
molecular mechanism of ovarian cancer metastasis in peritoneum,
it will provide insights into developing novel treatment to
compensate current standard-of-care treatments for ovarian
cancer.
Ovarian cancer metastasizes generally through direct dissemi-
nation from the primary site into peritoneal cavity, without
intravasation and extravasation of blood vessels.4 In fact, most of
patients with advanced ovarian cancer present with omental
metastasis.5,6 In omentum, stromal ﬁbroblasts are the second most
numerous cell types.7 The role of stromal ﬁbroblasts and cancer-
associated ﬁbroblasts (CAFs) in tumor progression has been
described. The factors, secreted by stromal ﬁbroblasts or CAFs,
transduce signals to cancer cells as well as to themselves
establishing reciprocal reinforcement of growth and progression
signals in various types of cancer.1,8 The growth of metastatic
cancer cells in distant sites after dissemination termed ‘metastatic
colonization’. This process is thought to be critical for the survival
of remaining microscopic tumor residuals after surgical debulking
and development of chemo-resistance ovarian tumor.9,10 The
molecular mechanism of how stromal ﬁbroblasts promotes
metastatic colonization of ovarian cancer in omental tissue
microenvironment, however, remains largely unknown.7
Three-dimensional (3D) organoid models emulate a more
physiologically relevant microenvironment in cancer than two-
dimensional (2D) monolayer cell culture.7,11,12 In this study, we
applied a 3D organoid co-culture model to investigate if normal
stromal ﬁbroblasts promote metastatic colonization of ovarian
cancer, and to investigate the reciprocal paracrine signaling
between cancer cells and stromal ﬁbroblasts that promotes
peritoneal metastasis of ovarian cancer.
RESULTS
Stromal ﬁbroblasts enhance colony formation of metastatic
ovarian cancer cells in 3D organoid model
To investigate how the omental microenvironment (that is, stromal
ﬁbroblasts) affects metastatic colonization of ovarian cancer, we
used a 3D organoid co-culture model based on the ‘seed and soil’
hypothesis.13 We embedded normal human stromal ﬁbroblasts
(WI38) with extracellular matrix (ECM; Matrigel) in culture
chambers, followed by overlaying a single-cell suspension of
metastatic human ovarian cancer cells (SKOV3; a human ovarian
cancer adenocarcinoma cell line derived from ascites) on the ECM-
ﬁbroblast mixture. Our results showed that SKOV3 cells formed
colonies with or without WI38 ﬁbroblasts. The number of SKOV3
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cancer colonies formed in ECM with WI38 ﬁbroblasts was
signiﬁcantly higher than that in ECM without WI38 ﬁbroblasts,
Moreover, the colonies co-cultured with WI38 ﬁbroblasts were
signiﬁcantly larger in size (Figure 1a). Our results indicated that
stromal ﬁbroblasts enhance the colony formation of metastatic
ovarian cancer cells in 3D organoid culture.
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Figure 1. For caption see page 3578.
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De novo expression of a group of cytokines in 3D organoid co-
culture of metastatic ovarian cancer cells and stromal ﬁbroblasts
We then compared the cytokine production of 3D organoid co-
culture (SKOV3+WI38) with 3D monocultures (WI38 or SKOV3
alone) by cytokine antibody array. Out of the 174 cytokines being
detected, 116 were co-expressed by the conditioned medium
(CM) of the stromal ﬁbroblast monoculture (WI38) and co-culture
(SKOV3+WI38), suggesting these cytokines are derived from
stromal ﬁbroblasts (Figure 1b; Cluster 3: Fibroblast-speciﬁc
cytokines). A group of 25 cytokines was predominantly expressed
by the monoculture of metastatic ovarian cancer cells (SKOV3;
Figure 1b; Cluster 1: Cancer-speciﬁc cytokines). Notably, a group of
16 cytokines was uniquely expressed by the co-culture (SKOV3
+WI38), including CXCL5, CXCL6, TGF-α, MMP-9, PECAM-1, PIGF,
Siglec-5, IL-2 R, VE-cadherin, MMP-13, TIMP-4, IGFBP-1, b-NGF, Axl,
and CXCL16 (Figure 1b; Cluster 2: De novo expressed cytokines).
De novo expression of TGF-α is induced in stromal ﬁbroblasts co-
cultured with metastatic ovarian cancer cells
Transforming growth factor alpha (TGF-α) is a key growth factor in
ovarian cancer microenvironment.14–16 Here we investigated the
source of de novo expression of TGF-α in our 2D co-culture models,
including 1) SKOV3+WI38, and 2) PEO1 (another metastatic human
ovarian cancer cell line derived from ascites17)+WI38. By ELISA, we
conﬁrmed higher levels of soluble TGF-α in CM from 2D co-cultures
(SKOV3+WI38 and PEO1+WI38) when compare to CM of 2D
monoculture (Supplementary Figure 1a). We isolated the meta-
static ovarian cancer cells from stromal ﬁbroblasts by magnetic
microbeads isolation kit (Figure 2a). Purity of the isolation was
high. When applying cell surface expression of CD44 as a marker
of human stromal ﬁbroblasts,18 we detected 85% of CD44-positive
cells in the ﬁbroblast isolations by ﬂow cytometry (Supplementary
Figure 2). We then measured the mRNA levels of TGF-α of isolated
metastatic ovarian cancer cells and stromal ﬁbroblasts from 2D co-
cultures and compared to those from monocultures of SKOV3,
PEO1 or WI38 alone (Figure 2a). The mRNA levels of TGF-α of
isolated WI38, but not ovarian cancer cells, from the 2D co-
cultures (SKOV3+WI38 and PEO1+WI38), were signiﬁcantly higher
than those from 2D monocultures (Figure 2b and Supplementary
Figure 1b). Our results indicated that stromal ﬁbroblasts co-
cultured with metastatic ovarian cancer cells induce de novo
expression of TGF-α.
Ovarian cancer cells secrete TNF-α that induces de novo
expression of TGF-α in stromal ﬁbroblasts through NF-κB signaling
Next, we examined if the cancer-speciﬁc cytokine(s), which were
predominantly expressed by the 3D monoculture of SKOV3 cells
(Figure 1b; Cluster 1: Cancer-speciﬁc cytokines), are involved in
inducing the TGF-α transcription in stromal ﬁbroblasts. We treated
WI38 ﬁbroblasts with the conditioned medium of metastatic ovarian
cancer cells (SKOV3 or PEO1), and found that TGF-α levels in WI38
ﬁbroblasts were signiﬁcantly up-regulated (Figure 2c). Treatment
with recombinant human (rh) cancer-speciﬁc cytokines, including
TNF-α (tumor necrosis factor alpha; 300 fold), IL-1β (interleukin-1
beta; 42.9 fold), and TNF-β (lymphotoxin; 20.6 fold), also showed
signiﬁcant up-regulation of TGF-α in WI38 ﬁbroblasts (Figure 2d). We
then showed the treatment with TNF-α neutralization antibodies
abolished the rhTNFα-induced TGF-α expression in WI38 ﬁbroblasts
(Figure 2e), conﬁrming that TNF-α is the key cytokine that induces
TGF-α induction in stromal ﬁbroblasts.
Besides, in our cytokine antibody array data, TNF-α protein
expression level in the conditioned medium decreased substan-
tially in co-culture when compared to that of SKOV3 ovarian
cancer cell monoculture. However, our qRT-PCR data showed that
there was no change in the mRNA level of TNF-α in either mono-
or co-culture cells (Supplementary Figure 3). Since we showed that
TNF-α is the key cytokine that induced TGF-α in stromal
ﬁbroblasts, our results suggested that the ﬁbroblasts actively
uptake the TNF-α in conditioned medium.
The classical TNFα-regulated gene expression involves activa-
tion of NF-κB signaling pathway,19 and three critical NF-κB binding
sites were identiﬁed in the human TGF-α promoter region.20 Here
we inhibited the NF-κB signal pathway in WI38 ﬁbroblasts by Bay
11-7082 (BAY) prior to rhTNF-α stimulation, and found that the
treatment of BAY signiﬁcantly reduced the TNFα-induced TGF-α
expression (Figure 2f). For p65/p50 heterodimer is the most
common form of NF-κB in ﬁbroblasts,21 we had studied the
protein expression of cytoplasmic and nuclear p50 and p65 in
stromal ﬁbroblasts. Nuclear translocation of p50 and p65 was
detected in TNFα-stimulated WI38 ﬁbroblasts, while pre-treatment
with BAY reduced such nuclear translocation (Figure 2f). Addi-
tionally, the mRNA level of TNF-α was signiﬁcantly higher in
metastatic ovarian cancer cells (SKOV3 and PEO1) when compared
to those in stromal ﬁbroblasts (WI38; Figure 2g). Taken together,
our results suggested that TNF-α secreted by metastatic ovarian
cancer cells induces de novo expression of TGF-α in stromal
ﬁbroblasts through NF-κB signaling.
Promoter DNA hypomethylation and chromatin remodeling
regulate TNF-α over-expression in human ovarian cancer cells
Although TNF-α is over-expressed in ovarian cancer,22 its underlying
mechanism is not known. Here, we conﬁrmed that TNF-α is
signiﬁcantly over-expressed in human ovarian cancer by comparing
the mRNA levels of normal ovarian surface epithelial tissue (Normal
Ov; n=10) to tumor tissue (OvCa Tumors; n=26) from primary
ovarian cancer (including serous subtypes; Figure 3a). A recent
integrative proteomic proﬁling study of ovarian cancers indicates
human fallopian tube secretory epithelial cells (FTSEC) are one
possible origin of high-grade serous ovarian cancer (HGSOC).23
Therefore, we included primary FTSEC (n=9) in the TNF-α mRNA
expression study, and found high expression levels of TNF-α in
primary FTSEC (Figure 3a). TNF-α is also over-expressed in human
ovarian cancer cell lines (n=15) when compared with non-malignant
hTERT-immortalized human ovarian surface epithelial (IOSE) cell lines
Figure 1. Stromal ﬁbroblasts enhance colony formation of metastatic ovarian cancer cells in three-dimensional (3D) organoid model with de-
novo expression of 16 cytokines. (a) Schematic representation of 3D organoid co-culture model (left, upper panel). Normal stromal ﬁbroblasts
(WI38) were mixed with extracellular matrix (ECM; BD Matrigel™) and placed at the bottom of chamber slides. Single-cell suspension of
metastatic ovarian cancer cells (SKOV3) was then overlaid on top of ECM with WI38. Monoculture of SKOV3 with ECM alone was served as
controls. The data represents means± s.e.m. from three independent experiments. ***Po0.001, *Po0.05 (Mann-Whitney U test).
(b) Conditioned medium (CM) from ECM alone (Matrigel), 3D monoculture of WI38, 3D monoculture of SKOV3, and 3D organoid co-
culture model (SKOV3+WI38) were collected on day 4 (left, upper panel) and their relative protein expressions of a total of 174 cytokines were
compared using cytokine antibody array (RayBiotech AAH-CYT-G2000-4). The signal was then normalized by the internal positive control and
subject to clustering analysis using DChip software (left, lower panel). A panel of cancer-speciﬁc cytokines was identiﬁed in the CM of 3D
organoid monoculture of SKOV3 ovarian cancer cells (right, upper panel). TNF-α was indicated by a red arrow. De-novo expression of 16
cytokines was identiﬁed in the CM of 3D organoid co-culture (right, lower panel). TGF-α was indicated by a red arrow. (Blue: low expression
level; White: no change; Red: high expression level).
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(n=5) and immortalized FTSEC cell lines (n=2; Figure 3a). Individual
analysis showed that TNF-α is over-expressed in 5 human ovarian
cancer cell lines, including IGROV-1, PEO1 (likely high-grade serous cell
line), TOV21G, OVSAHO (likely high-grade serous cell line), and
UWB1.289 cells (Figure 3b), whereas low levels of TNF-α were
detected in all IOSE cell lines and FTSEC cell lines being examined.
Human TNF-α is located at 6p21.3, whereas DNA hypomethyla-
tion at 6p21.3 is commonly found in HGSOC.24 Using MethyLight
assay, we showed that high levels of DNA methylation of TNF-α
promoter were detected in cell lines with low TNF-α levels, while a
signiﬁcant reduction of DNA methylation corresponded with the
ovarian cancer cell lines with high levels of TNF-α (that is, IGROV-1,
PEO1, TOV21G, OVSAHO, and UWB1.289 cells; Figure 3c). This
observation was conﬁrmed by bisulﬁte genomic sequencing
(Figure 3d), indicating that DNA hypomethylation in TNF-α
promoter correlates with TNF-α over-expression in human ovarian
cancer cells. We then treated TOV112D, an ovarian cancer cell line
that expresses low level of TNF-α, with a DNA methyltranferase
inhibitor, 5-aza-2’-deoxycytidine (AZA). AZA signiﬁcantly up-
regulated the TNF-α mRNA level, while reducing the DNA
methylation level of TNF-α promoter in the ovarian cancer cells
(Figure 3e and Supplementary Figure 4). Moreover, there is a
negative correlation between TNF-α mRNA expression and TNF-α
promoter methylation in ovarian serous cystadenocarcinoma from
TCGA study (Supplementary Figure 5). These results indicate DNA
hypomethylation regulates active endogenous gene expression of
TNF-α promoter in human ovarian cancer.
Speciﬁc histone tail modiﬁcations have been shown to be
associated with active and inactive CpG promoters.25 For instance,
acetylation of histone H3 lysine 9 (H3K9) and methylation of
histone H3 lysine 4 (H3K4) are important for the transcriptional
activation of CpG island promoters.26 Here, we treated TOV112D
cancer cells with histone deacetylase (HDAC) inhibitor trichostatin
A (TSA) or histone methyltransferase (HMTase) inhibitor BIX01294,
but showed no signiﬁcant changes in their mRNA levels of TNF-α
after treatment (Figure 3e and Supplementary Figure 4). Our ChiP-
qPCR analysis also showed no enrichment of acetylated H3K9/14
and acetylated H4K5ac at the TNF-α promoter of the ovarian
cancer cell lines with high levels of TNF-α (IGROV-1 and TOV21G)
when compared to those with low levels (IOSE20C2, IOSE25C2,
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Figure 2. De-novo expression of TGF-α in stromal ﬁbroblasts was induced by TNF-α secreted by ovarian cancer cells through NF-κB signaling.
(a) Schematic representation depicting the separation between stromal ﬁbroblasts (blue) and ovarian cancer cells (red) from two-dimensional
(2D) co-culture by magnetic micro-beads isolation kits (MACS). Ovarian cancer cells were ﬁrst isolated by ﬁbroblasts depletion and stromal
ﬁbroblasts were isolated by positive selection using anti-ﬁbroblast microbeads. (b) The mRNA expression levels of TGF-α of the isolated cells
(cancer cells or ﬁbroblasts) from 2D co-cultures (SKOV3+WI38 or PEO1+WI38) were determined by qRT-PCR and compared to those from 2D
monocultures (SKOV3, PEO1 or WI38 alone). (c) The mRNA expression levels of TGF-α were examined in WI38 ﬁbroblasts after treatments with
CM of SKOV3 or PEO1 cells. Treatments with CM of WI38 ﬁbroblasts were served as controls. (d) The mRNA expression levels of TGF-α were
determined in WI38 ﬁbroblasts after treatments of 100 ng/ml recombinant human cytokines (TGF-β1, IL-4, LIGHT, TNF-β, IL-1β and TNF-α) for
24 h. PBS was served as controls. Fold change against PBS treatment was measured. (e) The mRNA expression levels of TGF-α were determined
in WI38 ﬁbroblasts after treatments of rhTNFα (100 ng/ml) with or without rhTNFα neutralizing antibodies (rhTNFα ab; 10 ng/ml) for 24 h.
Human IgG1 (IgG) was served as controls. (f) The mRNA expression levels of TGF-α (left panel), and protein expression of cytoplasmic (Cyto)
and nuclear (Nuc) p50 and p65 (right panel) were detected in WI38 ﬁbroblasts after treatments of rhTNFα (100 ng/ml) for 24 h with or without
pre-treatment of BAY 11-7082 (BAY, a NF-κB inhibitor; 1 μM) for 1 h. The mRNA of TGF-α expression was determined by qRT-PCR. Protein
expression of p50 and p65 in cytoplasmic and nuclear fraction was detected by Western blotting. β-actin was used for equal
loading. (g) The mRNA expression levels of endogenous TNF-α in 2D monoculture of WI38, SKOV3 and PEO1 cells were detected by qRT-PCR.
All data represents means± s.e.m. from three independent experiments. Statistical difference was determined by Mann-Whitney U test.
**Po0.01; ***Po0.001.
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and TOV112D; Figure 3f). These results indicate that transcription
of TNF-α promoter in human ovarian cancer cells is not regulated
by histone acetylation or histone methylation.
Chromatin remodeling that involves nucleosome positioning
has been implicated in the regulation of gene expression. In
particular, active CpG island promoters contain a nucleosome-
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depleted region (NDR) upstream to their transcription start sites
(TSSs) that allows the access transcriptional machinery to the
promoters, whereas inactive CpG island promoters lack this NDR.27
Here we used NOMe-Seq (Nucleosome Occupancy and Methy-
lome sequencing)28 to detect the accessibility of the GpC
methyltransferase to methylate GpC sites that are not bound by
the nucleosomes in TNF-α promoters of the human ovarian cancer
cell lines (IGROV-1 and TOV112D). Our results showed in IGROV-1
cells, the upstream of TSS of TNF-α promoter is accessible to GpC
methyltransferase, which indicates NDR is present that might
allow the binding of appropriate transcription factors (Figure 3g,
purple boxes). The presence of NDRs is correlated with high levels
of TNF-α expression and un-methylated status of TNF-α promoter
in IGROV-1 cells (refer to Figures 3b–d). In contrast, TOV112D cells,
which exhibit extensive methylation at TNF-α promoter and low
TNF-α levels, showed almost no accessibility to GpC methyltrans-
ferase at regions immediately upstream to the TSS (Figure 3g),
indicating NDR is absent.
Taken together, these results showed that promoter DNA
hypomethylation and chromatin remodeling regulate TNF-α over-
expression in human ovarian cancer cells.
Fibroblast-derived TGF-α promotes colony formation of metastatic
ovarian cancer cells in 3D organoid co-culture through EGFR
activation
We had shown metastatic ovarian cancer cells induce de novo
expression of TGF-α in stromal ﬁbroblasts in co-culture (Figure 1b).
Here, we showed that the treatment with rhTGF-α signiﬁcantly
enlarged the colony sizes of metastatic ovarian cancer cells
(SKOV3 or PEO1) in 3D monocultures (Figure 4b). We then
examined the EGFR (epidermal growth factor receptor) expression
in human ovarian cancer cell lines and non-malignant IOSE cells,
for EGFR is a receptor for TGF-α29 and is over-expressed by up to
62% of epithelial ovarian cancer and correlated with poor
outcome of ovarian cancer.30,31 We found that EGFR was over-
expressed in 10 out of 15 ovarian cancer cell lines and in 2 FTSEC
cell lines (Figure 4a). The mRNA levels of EGFR in primary ovarian
cancer tissues (OvCa tumors) and primary fallopian tube secretory
epithelial cells (FTSECs) were also signiﬁcantly higher than those in
normal ovarian epithelia (Normal Ov; Figure 4a). The pre-
treatment of an EGFR tyrosine kinase inhibitor (TKI), Tyrphostin
AG1478, signiﬁcantly abolished the rhTGFα-induced cancer colony
formation of the 3D monocultures of metastatic ovarian cancer
cells (Figure 4b), as well as the ﬁbroblast-induced colony
formation of metastatic ovarian cancer cells in our 3D organoid
co-cultures (SKOV3+WI38 and PEO1+WI38; Figure 4c). Given that
AG1478 did not affect cellular proliferation of monoculture of
WI38 ﬁbroblasts or ovarian cancer cells (SKOV3 and PEO1;
Supplementary Figure 6), our results suggested that EGFR is
involved in the TGF-α-mediated colony formation of metastatic
ovarian cancer.
Additionally, the co-culture of primary cultures of normal
stromal ﬁbroblasts (NOFs), which were isolated from human
omentum, with ovarian cancer cells (PEO1), also showed de novo
expression of TGF-α. The treatment with rhTNF-α also induced de
novo TGF-α expression in NOFs (Supplementary Figure 7a and b).
Here we showed NOFs also promote colony formation of
metastatic ovarian cancer cells in the 3D co-cultures (SKOV3
+NOFs and PEO1+NOFs), whereas treatment with AG1478
signiﬁcantly abolished such colony formation (Figure 4d). These
results suggested normal omental stromal ﬁbroblasts promote
colony formation of metastatic ovarian cancer cells through TGFα-
EGFR signaling.
We further repeated our 3D organoid experiments with two
clinically used EGFR-speciﬁc TKIs (Geﬁtinib and Erlotinib)
(Figure 5). Geﬁtinib and Erlotinib did not affect cellular prolifera-
tion of monoculture of WI38 ﬁbroblasts and ovarian cancer cells
(SKOV3 and PEO1; Supplementary Figures 6a and b). Pretreatment
with Geﬁtinib or Erlotinib signiﬁcantly suppressed the rhTGFα-
induced colony formation in 3D organoid monocultures of
metastatic ovarian cancer cells (Figure 5a: SKOV3 or PEO1), as
well as the ﬁbroblasts-induced colony formation of metastatic
ovarian cancer cells in 3D organoid co-cultures (Figure 5b: SKOV3
+WI38 and PEO1+WI38; Figure 5c: SKOV3+NOFs and PEO1+NOFs).
Our results therefore conﬁrmed that ﬁbroblast-derived TGF-α
promotes colony formation of metastatic ovarian cancer cells in
3D organoid co-culture through EGFR activation.
TGF-α activates AKT and MAPK signaling in metastatic ovarian
cancer cells through EGFR
The EGFR ligand-dependent activation triggers cell proliferation,
invasion and colonization in cancer cells by stimulating various
downstream signaling modules, which include phosphatidylinosi-
tol 3-kinase (PI3K)/Akt (PKB) pathway, Ras/Raf/MEK/ERK1/2 path-
way, STAT pathway, and Hippo/YAP pathway.32–35 Here, we
examined the phosphorylation status of EGFR, AKT, ERK1/2,
STAT1, STAT3 and YAP in metastatic ovarian cancer cells after
rhTGF-α treatment in a time-dependent manner (Figure 5d).
Phosphorylation of EGFR and ERK1/2 were detected in SKOV3 cells
after rhTGF-α stimulation, whereas phosphorylation of EGFR, AKT
and ERK1/2 were detected in PEO1 cells. No phosphorylation of
STAT1, STAT3 and YAP was detected in either PEO1 or SKOV3 cells
Figure 3. Promoter DNA hypomethylation and chromatin remodeling regulate TNF-α over-expression in human ovarian cancer cells. (a) The
mRNA expression levels of TNF-α was compared between normal ovarian tissue (Normal Ov), micro-dissected fallopian tube secretory
epithelial cells from primary normal fallopian tube (Primary FTSEC) and micro-dissected tumor tissue from primary ovarian cancers (OvCa
tumors) (left), and between non-malignant hTERT-immortalized human ovarian surface epithelial (IOSE) cell lines, immortalized fallopian tube
secretory epithelial cells cell lines (FTSEC cell lines) and human ovarian cancer cell lines (OvCa cell lines)(right), by qRT-PCR. **Po0.01 and
***Po0.001 (Mann-Whitney U test). The data represents means± s.e.m. from three independent experiments. (b) The mRNA expression levels
of TNF-α in individual IOSE, FTSEC cell lines and human ovarian cancer cell lines were determined by qRT-PCR. (c) DNA methylation levels of
TNF-α promoter in IOSE, FTSEC cell lines and human ovarian cell lines were determined by MethyLight assay using sequence-speciﬁc probe
(indicated by the green bar). (d) DNA methylation status of TNF-α promoter in IOSE (IOSE20C2 and IOSE25C2) and human ovarian cell lines
(IGROV-1, TOV21G, and TOV112D) was investigated by bisulﬁte genomic sequencing. (White circles, unmethylated CpGs; Red circles,
methylated CpGs). Bisulﬁte-speciﬁc PCR primers (BSL and BSR) was indicated by black arrows. (e) The mRNA expression of TNF-α gene and
DNA methylation of TNF-α promoter were determined in TOV112D ovarian cancer cells after treatment of 5-aza-2’-deoxycytidine (AZA),
trichostatin A (TSA), or methyltransferase inhibitor (BIX01294) for 72 h. DMSO was served as controls. The mRNA expression levels of TNF-α
were determined by qRT-PCR (left, upper panel). DNA methylation status was detected by MethyLight assay (left, lower panel) and bisulﬁte
genomic sequencing (right). (f) Chromatin immunoprecipitation (ChIP) was performed in the cell lines with low (IOSE20C2, IOSE25C2, and
TOV112D) and high TNF-α expression (IGROV-1 and TOV21G), using antibodies for acetylated H3K9/14 (H3K9/14ac) (middle) and acetylated
H4K5 (H4K5ac) (right). Immunoprecipitated DNA was analyzed by qRT-PCR using primers ﬂanking TNF-α promoter region (as indicated by the
red bar in (c). Expression of TNF-α transcript in IOSE20C2, IOSE25C2, IGROV-1, TOV21G and TOV112D was shown for reference (left; excerpt
from b). (g) Nucleosome-depleted region (NDR) of TNF-α promoter was detected in cell line with high TNF-α expression (IGROV-1), but not in
cell line with low TNF-α expression (TOV112D), using high-resolution nucleosome positioning assay (NOMe-Seq). (White circles, unmethylated
CpGs/GPCs; red circles, methylated CpCs; blue circles, methylated GpGs; purple boxes, NDR).
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after rhTGF-α treatment. We further found that treatments of
AG1478, Geﬁtinib, or Erlotinib abolished the TGFα-induced
phosphorylation of EGFR and ERK1/2 in SKOV3 cells and phospho-
rylation of EGFR, AKT and ERK1/2 in PEO1 cells (Figure 5e). These
results indicate TGF-α activates AKT and ERK1/2 signaling in
metastatic ovarian cancer cells through EGFR.
Stromal ﬁbroblasts promote peritoneal metastasis of ovarian
cancer in vivo through activation of EGFR
To investigate if stromal ﬁbroblasts promote peritoneal metastasis
of ovarian cancer in vivo, we set up the following orthotopic
ovarian cancer xenograft experiment. We injected a mixture of
metastatic human ovarian cancer SKOV3 cells (1 ´ 107) and WI38
stromal ﬁbroblasts (1 ´ 106) intraperitoneally into athymic nude
mice. Mice injected with SKOV3 cells alone (1 × 107) were served
as controls. Seven days after intraperitoneal injection, the tumor
bearing mice (both the groups injected with SKOV3+WI38 and
with SKOV3 alone) were treated with either oral administration of
Geﬁtinib (50 mg/kg/day) or 1% tween 80 in saline for 4 weeks
(Figure 6a). Metastatic ovarian tumor nodules were found in
peritoneal cavity of mice, and they were located mainly in
intestine, mesentery, liver, and spleen (Supplementary Figure 8).
Our result showed that in the group injected with SKOV3 alone,
the tumor weight and number of tumor nodules with Geﬁtinib
treatment (n= 5) showed no signiﬁcant difference from those with
saline treatment (n= 5). On the other hand, the tumor weight and
number of tumor nodule in the saline-treated mice injected with
SKOV3+WI38 (n= 5) was signiﬁcantly higher (~2.25 fold and ~ 2.72
fold, respectively) when compared to the saline-treated mice
injected with SKOV3 alone (n= 5; Figure 6b), indicating stromal
ﬁbroblasts in the peritoneal microenvironment promote meta-
static colonization of ovarian cancer in vivo. Furthermore, the
tumor weight and number of tumor nodules were signiﬁcantly
lower in the Geﬁtinb-treated mice injected with SKOV3+WI38
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Figure 4. TGF-α and ﬁbroblasts promote colony formation of metastatic ovarian cancer cells in 3D organoid co-culture through activation of
EGFR. (a) Protein expression of EGFR in IOSE, FTSEC, and human ovarian cancer cell lines was detected by Western blotting. β-actin was used
for equal loading (left panel). mRNA expression of EGFR was compared between normal ovarian tissue (Normal Ov), micro-dissected fallopian
tube secretory epithelial cells from primary normal fallopian tube (Primary FTSEC) and micro-dissected tumor tissue from primary ovarian
cancers (OvCa tumors) by qRT-PCR (right panel). * Po0.05 and **Po0.01 (Mann-Whitney U test). The data represents means± s.e.m. from
three independent experiments. (b–d) Phase-contrast images (100x magniﬁcation) of ovarian cancer colonies (SKOV3 or PEO1) were captured
on day 8 in 3D organoid cultures, including 3D monoculture of ovarian cancer cells treated with rhTGF-α (b), 3D organoid co-culture with WI38
ﬁbroblasts (c) and 3D organoid co-culture with primary normal omental ﬁbroblasts (NOFs) (d) (upper panels). Treatments of AG1478 were also
performed. DMSO was served as vehicle controls. Diameter of cancer colonies in 10 ﬁelds was measured (Arbitrary unit) in phase-contrast
images, and their differences in treatment groups were compared with the DMSO control groups (lower panels). **Po0.01 and ***Po0.001
(Mann-Whitney U test). The data represents means± s.e.m. from two independent experiments, respectively.
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(n= 5) when compared to the saline-treated mice injected with
SKOV3+WI38 (n= 5; Figure 6b), indicating EGFR activation is
involved in promoting peritoneal metastasis of ovarian cancer by
stromal ﬁbroblasts in vivo.
A TNFα-TGFα-EGFR interacting loop is present in the
microenvironment of omental metastases of ovarian cancer
Using the ﬁbroblast-speciﬁc marker (α-SMA) and human
ﬁbroblast-speciﬁc marker (CD44), we found stromal ﬁbroblasts in
the tumor metastases from the mice injected with SKOV3+WI38,
but not in those injected with SKOV3 alone. The study of protein
expression proﬁles in omental tumor metastases from the mice
injected with SKOV3+WI38 showed that both TNF-α and EGFR
were expressed in SKOV3 cancer cells, whereas TGF-α was
expressed in α-SMA/CD44-positive stromal ﬁbroblasts (WI38;
Figure 6c).
We also examined the protein expression proﬁles of TNF-α,
TGF-α, and EGFR in serial sections of omental metastases
from patients with advanced ovarian cancer (16 cases). We scored
the percentage of stromal ﬁbroblasts that showed positive
TGF-α reactivity, and the intensity of positive TGF-α signal in
stromal ﬁbroblasts. We also scored the percentage of ovarian
cancer cells that showed positive TNF-α and EGFR reactivity, and
the intensity of positive TNF-α and EGFR signal in ovarian cancer
cells. Among these 16 samples, two of them (O-648 and O-682)
showed both strong TGF-α intensity in high percentage of stromal
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Figure 5. Fibroblasts-derived TGF-α promotes colony formation of metastatic ovarian cancer cells in 3D organoid co-culture through activation
of EGFR, and TGF-α activates AKT and MAPK signaling in metastatic ovarian cancer cells through EGFR. (a-c) Phase-contrast images (100x
magniﬁcation) of ovarian cancer colonies (SKOV3 or PEO1) were captured on day 8 in 3D organoid cultures, including 3D monoculture of
ovarian cancer cells treated with rhTGF-α (100 ng/ml) (a); 3D organoid co-culture with WI38 ﬁbroblasts (b); and 3D organoid co-culture with
NOFs (c) (upper panel). Treatment of Geﬁtinib (1 μM) or Erlotinib (1 μM) was performed. DMSO was served as vehicle controls. Diameter of
cancer colonies in 10 ﬁelds was measured (Arbitrary unit) in phase-contrast images. The sizes of cancer colonies in the treatment groups were
compared with the DMSO control groups (lower panel). **Po0.01 and ***Po0.001 (Mann-Whitney U test). The data represents means± s.e.m.
from two independent experiments. (d) Phosphorylation of EGFR, AKT, ERK1/2, STAT1, STAT3 and YAP were examined in ovarian cancer cells
(SKOV3 and PEO1) after treatment of rhTGF-α in a time-dependent manner by Western blotting. β-actin was served as loading controls.
(e) Phosphorylation of EGFR, AKT, ERK1/2 were examined in ovarian cancer cells (SKOV3 and PEO1) after treatments with 100 ng/ml rhTGF-α±1 μM
TKIs (AG1478, Geﬁtinib or Erlotinib) by Western blotting. DMSO was served as controls. SKOV3 and PEO1 were pre-treated with TKIs for 2 h
before stimulating with rhTGF-α for 15 min.
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ﬁbroblasts, and strong TNF-α and EGFR intensities in high
percentage of ovarian cancer cells (Supplementary Table 3). Most
importantly, in these two omental metastases (O-648 and O-682),
both TNF-α and EGFR were expressed in metastatic ovarian cancer
cells, whereas TGF-α was expressed in adjacent αSMA-positive
omental stromal ﬁbroblasts (Figure 6d). The distinctive localization
of TNF-α, TGF-α, and EGFR in tumor metastases suggested a loop
of cancer-stroma-cancer interaction, i.e. TNF-α-TGFα-EGFR, is
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Figure 6. Stromal ﬁbroblasts promote peritoneal metastasis of ovarian cancer in vivo through activation of EGFR, and a TNFα-TGFα-EGFR
interacting loop presents in the microenvironment of omental metastases of ovarian cancer. (a) Schematic diagram showing the use of
orthotopic ovarian cancer xenograft model to evaluate the effect of stromal ﬁbroblasts on peritoneal metastasis of ovarian cancer in vivo, and
the effect of EGFR activation on ﬁbroblast-induced peritoneal metastasis of ovarian cancer in vivo. (b) Macroscopical morphology of metastatic
tumor nodules in orthotopic xenografts was shown (green arrow and green stroke). The weight and number of dissected metastatic tumor
nodules were quantiﬁed (right). The weight and number of metastatic tumor nodules were compared between the saline-treated mice
injected SKOV3+WI38 (n= 5) and the saline-treated mice injected with SKOV3 alone (n= 5), and also between the Geﬁtinib-treated mice
injected with SKOV3+WI38 (n= 5) and the saline-treated mice injected with SKOV3+WI38 (n= 5). * Po0.05 (Student's t test). (c)
Immunohistochemical staining for TNF-α, TGF-α, EGFR, CD44 and α-SMA in serial sections of metastatic tumor nodules collected from the
saline-treated mice injected with SKOV3 alone or with SKOV3+WI38. Fibroblasts were identiﬁed by positive signal of α-SMA and CD44 staining.
Image was captured at 200x magniﬁcation. (Red arrow: cancer cells and black arrow: ﬁbroblasts) (d) Immunohistochemical staining for TNF-α,
TGF-α, EGFR, and α-SMA in serial sections of omental metastases from patients with advanced ovarian cancer. Image was captured at 200x
magniﬁcation. (T: ovarian tumor cells and F: omental stromal ﬁbroblasts).
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present in the microenvironment of omental metastases of
ovarian cancer.
DISCUSSION
In this study, we uncover a loop of cancer-stroma-cancer
interaction that promotes peritoneal metastasis of ovarian cancer
via TNFα-TGFα-EGFR. We demonstrate that 1) TNF-α is over-
expressed in metastatic ovarian cancer cells by promoter DNA
hypomethylaton and chromatin remodeling; 2) TNF-α secreted by
ovarian cancer cells then induces de novo expression of TGF-α in
omental stromal ﬁbroblasts through NF-κB signaling; 3) ﬁnally the
ﬁbroblast-derived TGF-α promotes metastasis colonization of
ovarian cancer cells through activation of EGFR, AKT and ERK1/2
signaling (Figure 7).
TNF-α is frequently over-expressed in ovarian cancer,36,37 and its
over-expression is associated with the increase of tumor grade,38
but the exact molecular mechanism of TNF-α over-expression is
not completely known. One of the mechanisms is that high levels
of TNF-α mRNA in ovarian cancer cells is stabilized by autocrine
regulation of TNF-α.22 In this study, we showed that over-
expression of TNF-α mRNA correlates with DNA hypomethylation
and chromatin remodeling in TNF-α promoter region in ovarian
cancer cell lines. Interestingly, we have also detected DNA
methylation at the promoter region of LTA and exon 4 (CpG 75)
of LTB, which are the neighboring genes of TNF-α located at the
LTA/TNF/LTB locus at 6p21.3 (Supplementary Figure 9a). DNA
methylation status at promoter region of LTA and exon 4 of LTB,
however, does not correlate with the over-expression of LTA and
LTB in ovarian cancer cell lines, respectively (Supplementary
Figures 9 and 10). These results therefore conﬁrmed that DNA
hypomethylation of TNF-α promoter at 6p21.3 is speciﬁc for TNF-α
over-expression in ovarian cancer cells.
A recent report showed hypomethylation of 60 CpGs (1 Mb
away from LTA/TNF/LTB locus) located in 6p21.3 is associated with
cis up-regulation of genes enriched in immune response
processes (TAP1, PSMB8, PSMB9, HLA-DOB1, HLA-DOB2, HLA-DMA,
and HLA-DOA), increased CD8-T cell tumor inﬁltration, trans-
regulation of genes in immune-related pathway, and improved
prognosis in high-grade serous epithelial ovarian cancer.24 Although
expression of TNF-α (due to promoter DNA hypomethylation) is
associated with poor outcome, this paradox could be explained by
hypomethylation of TNF-α promoter and hypomethylation of
those 60 CpGs are independent events in ovarian cancer.
TGF-α is one of the ligands for EGFR, which regulates growth
and invasion in ovarian cancer cells through autocrine production
of TGF-α and activation of EGFR downstream signaling.16,39,40 We
have shown that SKOV3 cells express very low levels of TGF-α,
whereas PEO1 cells express substantial amount of TGF-α. More-
over, TGF-α expression showed no signiﬁcant difference after
rhTNF-α treatment in both SKOV3 and PEO1 cells (Supplementary
Figures 7c and 7d). This result suggests that cancer cell-
autonomous TGF-α is not a key event for promoting metastatic
colonization of ovarian cancer cells.
EGFR is a potential therapeutic target in ovarian cancer because
it is over-expressed in about 30–60% of ovarian cancers and its
expression is associated with poor prognosis and decreased
therapeutic responsiveness.31,41,42 Consistent with our data,
several preclinical studies have demonstrated that Geﬁtinib
suppresses ovarian cancer intra-abdominal dissemination or
peritoneal metastasis in xenograft models,43–45 indicating that
cell-autonomous EGFR in ovarian cancer cells is critical for their
metastatic colonization in peritoneum. Most of the clinical trials,
however, showed limited or no clinical response of Geﬁtinib or
Erlotinib in ovarian cancer patients.46–48 Those results indicated
that the biological mechanism of EGFR in ovarian cancer may
different from those EGFR-TKIs sensitive disease, such as NSCLC.
The limited response can be accounted by the lack of EGFR
activating mutation,30,49 or the presence of alterative activated
pathways such as MAPK/ERK and PI3K/AKT/mTOR pathway due to
the mutation of KRAS, PIK3CA or PTEN in ovarian cancer.50–52
These factors may hinder the inhibition of a solitary signal
transduction pathway in ovarian cancer by Geﬁtinib or Erlotinib.
Report showed that combination of Geﬁtinib or Erlotinib and PI3K
inhibitor showed synergistic activity against ovarian cancer.53
Furthermore, a recent study demonstrated that combination of IL6
antibodies and Geﬁtinib showed more effective in reducing
ovarian tumor growth when compared with Geﬁtinib treatment
alone.44 These studies further indicated that EGFR participated in
the development of ovarian cancer is distinct from the diseases
sensitive to TKIs. Therefore, more studies are needed to fully
dissect the role of EGFR in ovarian cancer, as a result of developing
an ovarian cancer-speciﬁc EGFR targeting therapy such as
combination therapies or the use of next generation EGFR-TKIs.
MATERIALS AND METHODS
Patients and specimens
A total of 26 specimens of primary ovarian cancer (Supplementary Table 1)
and 16 specimens of omental metastases were recruited from patients
with epithelial ovarian cancer (Supplementary Table 2). Nine specimens of
normal fallopian tube and 10 specimens of normal ovary were recruited
from women who underwent oophorectomy for non-malignant condi-
tions. Study subjects were recruited at our unit. Informed consent was
obtained from each patient prior surgery. Histological typing of tumor was
classiﬁed according to the World Health Organization criteria, whereas
clinical staging follows the International Federation of Gynecology and
Obstetrics standards. The research protocol was approved by the
Institutional Clinical Research Ethics Committee.
2D co-culture model
Routine cell culture methods have been reported.54 For 2D co-culture,
2 × 105 of WI38 ﬁbroblasts were ﬁrst seeded in assigned wells in 6-well
plates. One× 105 of ovarian cancer cells (SKOV3 or PEO1) were seeded into
the wells. Cancer cells were isolated by ﬁbroblasts depletion and
ﬁbroblasts were isolated by positive selection from 2D co-culture (SKOV3
+WI38 and PEO1+WI38) using anti-ﬁbroblast microbeads (Miltenyi Biotec,
Singapore) after 48 hr co-culture. Purity of isolated ﬁbroblasts was
determined by human speciﬁc CD44 antibodies (Abcam, Cambridge, UK)
using ﬂow cytometry FC500 (Beckmen Coulter, Indianapolis, IN, USA). FCS
Express software was used for data analysis.
TNF
EGFR
Normal omental  
stromal fibroblasts  
(NOF)
Metastatic  
colonization  
in omentum
TGF
Metastatic  
ovarian cancer cells 
(OvCa)
AKTp
TNF  promotor 
DNA 
hypomethylation  
and  
chromatin 
remodeling
p65
p50
TGFERK1/2p
p
Figure 7. Proposed mechanism of a loop of cancer-stromal-cancer
interaction that promotes peritoneal metastasis of ovarian cancer
via TNFα-TGFα-EGFR. 1) The overexpression of TNF-α in metastatic
ovarian cancer cells is regulated by DNA hypomethylation and
chromatin remodeling of TNF-α promoter; 2) TNF-α secreted from
metastatic ovarian cancer cells induces de novo expression of TGF-α
in normal omental stromal ﬁbroblasts through NF-κB signaling; and 3)
TGF-α secreted by omental stromal ﬁbroblasts promotes metastatic
colonization of ovarian cancer cells through the activation of EGFR,
AKT and ERK1/2 signaling.
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Isolation and culture of primary omental ﬁbroblasts
Primary normal omental ﬁbroblasts were isolated from non-malignant
omental tissues of female patients. Omental tissue was dissociated using
gentleMACS dissociators (Miltenyi Biotec). Omental ﬁbroblasts were
isolated by positive selection using anti-ﬁbroblast microbeads (Miltenyi
Biotec).
3D organoid culture
Fibroblasts at 1 × 105 was mixed with 500 μl extracellular matrix (ECM;
Matrigel, BD Biosciences, San Jose, CA, USA) and loaded into each well of
chamber slide (Nunc Lab-Tek, Rochester, NY, USA). After the gel solidiﬁed,
ovarian cancer cells were seeded on top of the gel with a density of 1 × 104
cells in 500 μl complete medium per well and incubated for 8 days. To
investigate the effect of rhTGF-α, the 3D organoid monocultures were
treated with 100 ng/ml rhTGF-α (R&D System, Minneapolis, MN, USA). To
investigate the effect of tyrosine kinase inhibitors, the 3D organoid
monocultures or 3D organoid co-cultures were treated with 1 μM of
AG1478 (Sigma-Aldrich, Saint Louis, MO, USA), Geﬁtinib (Toronto Research
Chemicals, Canada), or Erlotinib (Toronto Research Chemicals).
Cytokine antibody arrays
Cytokines in conditioned medium from the 3D organoid culture were
determined by cytokine antibody array (AAH-CYT-G2000-4, RayBioTech,
Norcross, GA, USA). The array data was subjected to the DNA-Chip Analyzer
Software (DChip; http://www.dchip.org) for comparative analysis.
Quantitative real-time RT-PCR
Methods of quantitative real-time quantitative reverse transcription–PCR
have been reported.54 TaqMan primers and probes for TNF-α, TGF-α, EGFR,
and β-actin (Applied Biosystems) were used.
MethyLight
Bisulﬁte conversion was performed on 2 μg genomic DNA using EZ DNA
Methylation Kit (ZYMO Research, Irvine, CA, USA). EpiTect MethyLight PCR
Kit (Qiagen, Valencia, CA, USA) was used to analyze promoter DNA
methylation of TNF-α. Unmethylated forward primer (GTGTGTTTTTAAT
TTTTTAAATTTT), unmethylated reverse primer (CAACTACCTTTATATATCCC
TAAAAC), and unmethylated probe labeled with VIC (TTTTTGTGATGG
AGAAGAAATTGA) were used to detect unmethylated sequence of TNF-α
promoter. Methylated forward primer (GTGTGTTTTTAATTTTTTAAATTTT),
methylated reverse primer (CAACTACCTTTATATATCCCTAAAAC), and methy-
lated probe labeled with FAM (CGCGATGGAGAAGAAATCGAG) were used to
detect methylated sequence of TNF-α promoter.
Bisulﬁte Genomic Sequencing
The bisulﬁte converted DNA was ampliﬁed by nested PCR that tar-
geting the TNF-α promoter region. Primer sequences for PCR round 1, F:
5′-GTTAAGATTGAAATTAGTATTATGAGT-3′; R: 5′-AAAAATTAAAAACACACAA
ACATCAAA-3′. Primer sequences for PCR round 2, F: 5′-GTATTTTTGATG
TTTGTGTGTTTTTAA-3′; R: 5′-TCACTCAAAATACAACAAACAAAAA-3′. Target
PCR products were puriﬁed and cloned. Ten clones from each cell line were
isolated and sequenced.
Nucleosome occupancy and methylome sequencing (NOMe-Seq)
NOMe-Seq assay (Active Motif, CA, USA) was performed. Bisulﬁte-speciﬁc
PCR primers (F: 5′-TTAGAAGGAAATAGATTATAGATTTGG-3′; R: 5′-AAATCA
ATATATAAAAAAAAAAAAACC-3′) were used to amplify the TNF-α promoter
region. Target PCR products were puriﬁed and cloned. Ten clones from
each cell line were isolated and sequenced. GpC and CpG regions were
plotted for analyzing the methylation proﬁles and nucleosome occupancy.
Western blotting and immunohistochemistry
Methods of Western blotting and immunohistochemistry have been
reported.54 Antibodies for p50, p65, AKT, phospho-AKT, ERK, phospho-ERK,
STAT1, phospho-STAT1, STAT3, phospho-STAT3, YAP, phospho-YAP, EGFR
were purchased from Cell Signaling Technology (Danvers, MA, USA);
Antibodies for phospho-EGFR, TGF-α and TNF-α were purchased from
Santa Cruz, (Santa Cruz, CA, USA); β-actin antibody was purchased from
Sigma-Aldrich; α-SMA and human-CD44 antibody were purchased from
Abcam (Cambridge, UK).
Xenograft mouse model
All animal experiments were approved by The Chinese University of Hong
Kong Animal Experimentation Ethics Committee. Female nude mice, aged
3 to 4 weeks, were used as xenografts model. Twenty mice were divided
into two groups. One group of mice (n= 10) were injected intraperitoneally
with SKOV3 cells (1 × 107 cell/body). Another group of mice (n=10) were
injected intraperitoneally with the mixture of SKOV3 cells (1 × 107 cell/
body) and WI38 ﬁbroblasts (1 × 106 cell/body). Seven days after inocula-
tion, mice in each group (SKOV3 and SKOV3+WI38) were randomized into
treatment group (n= 5) and control group (n=5). For treatment group,
mice were oral administered with geﬁtinib (50 mg/kg/d). For control
group, mice were oral administered with equal volume of saline with 1%
tween 80. Mice were sacriﬁced on Day 40 after cells injection. Macroscopic
lesions were recorded and metastatic tumor nodules were dissected,
weighed and parafﬁn-embedded for immunohistochemical staining.
Statistical analysis
All data were presented as means± S.E.M. and analyzed using GraphPad
Prism 5.0 software (GraphPad Inc., Sandiego, CA, USA) from at least three
independent experiments. Statistical difference between groups was
determined by Student’s t test or Mann-Whitney rank-sum test. Po0.05
was considered as statistically signiﬁcant (*), Po0.01 as highly signiﬁcant
(**), and Po0.001 as extremely signiﬁcant (***).
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